Sources/Institution or study
2018 AHA/ACC cholesterol guideline
Named as the source for 5 optimal-range positions across 5 biomarkers on this site. How we verify ranges.
01
Every position on this site
One row per marker. The comparison column uses the same simple-range parser the rest of the site does, so it is left blank rather than guessed when a range is tiered, sex-split, or in a different unit than the lab interval.
| Marker | Their range | Vs. the lab reference interval | Where they stated it |
|---|---|---|---|
| Apolipoprotein B (ApoB) | ≥130 mg/dL is a risk-enhancing factor | not directly comparable | Cited document ↗Corresponds to an LDL-C of 160 mg/dL or more; the guideline suggests measuring ApoB when triglycerides are 200 mg/dL or higher |
| LDL Cholesterol | ≥70 mg/dL on a statin prompts add-on therapy in very high-risk ASCVD | not directly comparable | Cited document ↗Sets treatment thresholds rather than an optimal level; LDL-C of 190 mg/dL or more is treated without calculating risk |
| Lipoprotein (a) | ≥50 mg/dL (≥125 nmol/L) is a risk-enhancing factor | not directly comparable | Cited document ↗Measurement is relatively indicated with a family history of premature ASCVD |
| Triglycerides | Persistent ≥175 mg/dL is a risk-enhancing factor | not directly comparable | Cited document ↗ |
| hs-CRP (High Sensitivity C-Reactive Protein) | ≥2.0 mg/L is a risk-enhancing factor | not directly comparable | Cited document ↗Used to refine a borderline or intermediate 10-year risk estimate |